Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’...
BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...
BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.46%. September E-mini...
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.79%. September E-mini S&P futures (ESU25...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.58%. September E-mini S&P futures...